We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.40
Bid: 69.00
Ask: 71.40
Change: 1.20 (1.74%)
Spread: 2.40 (3.478%)
Open: 72.00
High: 73.00
Low: 71.40
Prev. Close: 69.00
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Jun 2020 12:15

RNS Number : 5533O
Novacyt S.A.
01 June 2020
 

 

Liquidity Agreement Monthly Update andTotal Voting Rights

 

Paris, France and Camberley, UK - 1 June 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

 

During the period from 1 May to 31 May 2020, Invest Securities purchased 2,750 ordinary shares at a maximum price of €4.55 and a minimum price of €3.20 and sold 1,750 ordinary shares at a maximum price of €4.99 and a minimum price of €3.74 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 May 2020, is 4,300.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 67,673,567. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

 

 

For further information, please refer to www.novacyt.com or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 27 June 2017 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €8.10 for an aggregate maximum purchase price of €100,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUAVRRRKUNRAR
Date   Source Headline
24th May 20197:00 amRNSPublication of Annual Report and Notice of AGM
17th May 20194:35 pmRNSConversion of Loan Notes
15th May 20195:30 pmRNSConversion of Loan Notes
13th May 20197:00 amRNSLaunch of Next-Generation qPCR Instrument
3rd May 20196:23 pmRNSConversion of Loan Notes
3rd May 20197:00 amRNSChange of Adviser
1st May 20195:30 pmRNSLiquidity Agreement
30th Apr 20197:00 amRNSFull Year 2018 Results
25th Apr 20197:00 amRNSUpdate on Notice of Full Year Results
23rd Apr 20197:00 amRNSConvertible Bond Facility
8th Apr 20197:00 amRNSExpanded Development Partnership with Immunexpress
1st Apr 20192:30 pmRNSLiquidity Agreement and Total Voting Rights
4th Mar 20197:00 amRNSLiquidity Agreement and Total Voting Rights
26th Feb 20197:00 amRNSFunding Update
1st Feb 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
22nd Jan 20197:00 amRNSRevenues Full Year 2018
2nd Jan 201912:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Dec 20187:00 amRNSTrading Update
21st Dec 20187:00 amRNSNovacyt launches two new molecular diagnostic kits
11th Dec 20187:00 amRNSUpdate on Strategic Review
6th Dec 20187:00 amRNSCompletion of q16 molecular diagnostics order
3rd Dec 20181:00 pmRNSLiquidity Agreement and Total Voting Rights
30th Nov 201812:06 pmRNSReplacement: Unsecured Debt Facility
27th Nov 20187:00 amRNS$3.0M supply agreement with Genesis Diagnostics
1st Nov 20185:45 pmRNSLiquidity Agreement
1st Oct 201810:51 amRNSLiquidity Agreement and Total Voting Rights
26th Sep 20187:00 amRNSNovacyt Half Year 2018 Results
13th Sep 20187:00 amRNSNovacyt Partners with Applied Microarrays
3rd Sep 201811:15 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 201810:30 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 20187:00 amRNSHalf Year Revenue Update
26th Jul 20187:00 amRNSRevenue update to be announced on 2 August 2018
2nd Jul 201811:45 amRNSLiquidity Agreement Update and Total Voting Rights
28th Jun 20187:00 amRNSAcquisition of ID Business from Omega Diagnostics
12th Jun 201811:45 amRNSReplacement - Results of Annual General Meeting
12th Jun 20187:00 amRNSResults of Annual General Meeting
5th Jun 20187:00 amRNSLaunch of New Product in Infectious Mononucleosis
1st Jun 20183:30 pmRNSLiquidity Agreement and Total Voting Rights
30th May 20186:30 pmRNSNew Unsecured Debt Facility
23rd May 20182:51 pmRNSPublication of Annual Report and Notice of AGM
1st May 20184:30 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Apr 20187:00 amRNSNovacyt Full Year 2017 Results
3rd Apr 20181:30 pmRNSLiquidity Agreement Update and Total Voting Rights
22nd Mar 20187:00 amRNSSigning of Assay Development Contract with GenePOC
1st Mar 20182:59 pmRNSLiquidity Agreement Update and Total Voting Rights
1st Feb 20183:15 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Jan 20189:32 amRNSNotification of major holdings
24th Jan 20187:00 amRNSNOVACYT REVENUES FULL YEAR 2017
2nd Jan 20181:30 pmRNSLiquidity Agreement Update and Total Voting Rights
2nd Jan 20187:00 amRNSPLACED IN TECHNOLOGY FAST 500 EMEA AWARDS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.